Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the period ending September 20, 2023. The report serves to furnish a press release regarding a regulatory update from the U.S. Food and Drug Administration (FDA) concerning the Company's De Novo Classification Request for breast cancer treatment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the receipt of an FDA response to the Company's De Novo Classification Request for breast cancer. The filing incorporates specific paragraphs and the "Forward Looking Statements" section of the associated press release by reference into the Company's Registration Statements on Form F-3 and Form S-8.
Guidance, Outlook, and Risks
The filing references "Forward Looking Statements" contained within the attached press release (Exhibit 99.1) but does not reproduce the specific text of the outlook, risks, or contingencies in the body of this Form 6-K. Investors must refer to the press release for details on the FDA response implications and future expectations.
Key Facts for Investor Verification
- Verify the specific content of the FDA response to the De Novo Classification Request for breast cancer in the attached press release (Exhibit 99.1).
- Confirm the status of the Company's Registration Statements (Form F-3 and Form S-8) which now incorporate the press release by reference.
- Note that no financial performance data is included in this specific filing.